The Respiratory Protection Effectiveness Clinical Trial (ResPECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01249625
Recruitment Status : Active, not recruiting
First Posted : November 30, 2010
Last Update Posted : March 5, 2018
Centers for Disease Control and Prevention
VA Office of Research and Development
University of Massachusetts, Amherst
Denver Health and Hospital Authority
Children's Hospital Colorado
VA Eastern Colorado Health Care System
VA New York Harbor Healthcare System
Michael Debakey Veterans Affairs Medical Center
Washington D.C. Veterans Affairs Medical Center
VA St. Louis Health Care System
Information provided by (Responsible Party):
Johns Hopkins University

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : January 2019
  Estimated Study Completion Date : January 2019
U.S. Department of Health and Human Services: Food and Drug Administration (2005). Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials. Rockville, MD: Food and Drug Administration.
Fisher LD, Dixon DO, Herson J, et al. (1990) Intention to treat in clinical trials. In: Peace KE (Ed.), Statistical issues in drug research and development (pp. 331-50). New York, NY: Marcel Dekker.
Hayes RJ and Moulton LH (2009) Cluster Randomised Trials. Chapman and Hall/CRC.
ICH Expert Working Group (1998). ICH Harmonised Tripartite Guideline, Statistical Principles for Clinical Trials E9, Current Step 4 version dated 5 February 1998. (last accessed 04 June 2017).

Publications automatically indexed to this study by Identifier (NCT Number):